Novel anti-cancer drug COTI-2 synergizes with therapeutic agents and does not induce resistance or exhibit cross-resistance in human cancer cell lines

• Saman Maleki Vareki ,

  Contributed equally to this work with: Saman Maleki Vareki, Kowthar Y. Salim

  Roles Data curation, Formal analysis, Investigation, Methodology, Project administration, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

  Affiliation Cancer Research Laboratory Program, Lawson Health Research Institute, London, Ontario, Canada

  ⨯
• Kowthar Y. Salim ,

  Contributed equally to this work with: Saman Maleki Vareki, Kowthar Y. Salim

  Roles Conceptualization, Formal analysis, Visualization, Writing – original draft, Writing – review & editing

  Affiliation Cotinga Pharmaceuticals (formerly Critical Outcome Technologies Inc.), London, Ontario, Canada

  ⨯
• Wayne R. Danter,

  Roles Conceptualization

  Affiliation Cotinga Pharmaceuticals (formerly Critical Outcome Technologies Inc.), London, Ontario, Canada

  ⨯
• James Koropatnick

  Roles Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing

  * E-mail: jkoropat@uwo.ca

  Affiliations Cancer Research Laboratory Program, Lawson Health Research Institute, London, Ontario, Canada, Department of Microbiology and Immunology, Western University, London, Ontario, Canada, Department of Pathology, Western University, London, Ontario, Canada, Department of Oncology, Western University, London, Ontario, Canada, Department of Physiology and Pharmacology, Western University, London, Ontario, Canada

  ⨯